

**Verici Dx plc**  
**("Verici Dx" or the "Company")**

**Investor Presentation**

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that Sara Barrington, CEO and David Anderson, CFO will provide a live presentation to investors via the Investor Meet Company platform on 11<sup>th</sup> July 2023 at 4:30pm BST. The presentation will include a strategic update and an overview of the preliminary results announced in June.

The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet Verici Dx Plc via:  
<https://www.investormeetcompany.com/verici-dx-plc/register-investor>

Investors who already follow Verici Dx Plc on the Investor Meet Company platform will automatically be invited.

A recording of the presentation and a PDF of the slides used will also be available on the Verici website [Results, Events, & Presentations | Verici Dx](#)

**Enquiries:**

**Verici Dx**  
Sara Barrington, CEO  
Julian Baines, Chairman

[www.vericidx.com](http://www.vericidx.com)  
Via Walbrook PR

**Singer Capital Markets (Nominated Adviser & Broker)**  
Aubrey Powell / Sam Butcher

**Tel: +44 20 7496 3000**

**Walbrook PR Limited**  
Paul McManus / Stephanie Cuthbert /  
Sam Allen

**Tel: +44 20 7933 8780** or [vericidx@walbrookpr.com](mailto:vericidx@walbrookpr.com)  
Mob: +44 7980 541 893 / +44 7796 794 663 /  
07502 558 258

**About Verici Dx plc** [www.vericidx.com](http://www.vericidx.com)

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology and collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

Verici Dx's two lead products are Tutivia™, a post-transplant test focused upon acute cellular rejection, including sub-clinical rejection and Clarava™, a pre-transplant prognosis test for the risk of early acute rejection. These products seek to measure how a patient is likely to respond, and is responding, to a kidney transplant. These products are underpinned by extensive patented and published scientific research from the leading Mount Sinai Medical Center, for which the Company holds an exclusive worldwide licence.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCBELLBXDLXBBF